Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-11-10
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Metformin; Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least 3 months

• No previous treatment for diabetes

• HbA1c between 7.0-12.0%

• Body Mass Index (BMI) between 19.0-40.0 kg/m2

Exclusion Criteria:

• Type 1 diabetes

• Known unstable/untreated proliferative retinopathy

• Uncontrolled treated/untreated hypertension

• Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures